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Abstract
Background:  Characterization of anti-malarial drug concentration profiles is necessary to
optimize dosing, and thereby optimize cure rates and reduce both toxicity and the emergence of
resistance. Population pharmacokinetic studies determine the drug concentration time profiles in
the target patient populations, including children who have limited sampling options. Currently,
population pharmacokinetic studies of anti-malarial drugs are designed based on logistical, financial
and ethical constraints, and prior knowledge of the drug concentration time profile. Although these
factors are important, the proposed design may be unable to determine the desired
pharmacokinetic profile because there was no formal consideration of the complex statistical
models used to analyse the drug concentration data.
Methods: Optimal design methods incorporate prior knowledge of the pharmacokinetic profile of
the drug, the statistical methods used to analyse data from population pharmacokinetic studies, and
also the practical constraints of sampling the patient population. The methods determine the
statistical efficiency of the design by evaluating the information of the candidate study design prior
to the pharmacokinetic study being conducted.
Results: In a hypothetical population pharmacokinetic study of intravenous artesunate, where the
number of patients and blood samples to be assayed was constrained to be 50 and 200 respectively,
an evaluation of varying elementary designs using optimal design methods found that the designs
with more patients and less samples per patient improved the precision of the pharmacokinetic
parameters and inter-patient variability, and the overall statistical efficiency by at least 50%.
Conclusion: Optimal design methods ensure that the proposed study designs for population
pharmacokinetic studies are robust and efficient. It is unethical to continue conducting population
pharmacokinetic studies when the sampling schedule may be insufficient to estimate precisely the
pharmacokinetic profile.
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Background
Despite significant progress in malaria control over the
last few years, malaria-related morbidity and mortality are
still considerable[1]. The contribution of inadequate dos-
age regimens (dose and frequency of administration) to
anti-malarial treatment failure and the emergence of
resistance has been underappreciated[2]. Most recom-
mended dosage regimens are based on studies in non-
pregnant adult patients, yet young children and pregnant
women are at the greatest risk of treatment failure and
often bear the brunt of the malaria burden[2]. Optimizing
current treatment regimens could provide major health
benefits and is a necessary prerequisite for malaria elimi-
nation. Effective treatment of malaria requires that the
dose and frequency of administration of the anti-malarial
drug provide drug concentrations over time (known as the
'concentration-time profile') sufficient to kill all of the
parasites in the body. This profile is determined by the
pharmacokinetic properties of the anti-malarial drug. In
endemic areas, young children have the least immunity
and the worst treatment responses. Anti-malarial pharma-
cokinetics often differ substantially between patients and,
therefore, need to be quantified precisely for all key target
populations, especially young children and pregnant
women. A recent pharmacokinetic study for sulphadox-
ine-pyrimethamine (SP) found that children, receiving
the same weight-adjusted SP dose as adults, had an area
under the drug concentration-time profile, for both sul-
phadoxine and pyrimethamine, that was half that
observed for adults [3]. The authors recommended that
the current SP dose for children needs to be revised.
Over the last two decades developments in statistical
methodology have allowed drug concentration-time pro-
files to be derived from patients providing only "sparse"
samples at random times[4,5]. Data from all patients are
modelled simultaneously using nonlinear mixed effects
modelling (also known as 'population pharmacokinetic
(PK) modelling'). This provides estimates of the mean
population PK parameters (e.g. clearance), the inter-indi-
vidual variability of the PK parameters, and the residual
variability (which includes intra-individual variability,
measurement errors and model misspecification). Addi-
tionally the introduction of liquid chromatography mass
spectrometry has revolutionized drug analysis and is a
highly sensitive assay with low limits of quantification
while at the same time permitting low (i.e. 25–50 ml)
sample volumes. The viability of field studies has been
considerably improved by the introduction of sensitive
assays using dried capillary whole blood spots taken on
filter paper. Thus, since the PK profile can be determined
from fewer blood samples per patient using nonlinear
mixed effects modelling, and that the drug concentration
can often be determined from blood taken by a simple
finger prick, it has become easier to include pregnant
women and young children in PK studies. PK studies,
which determine the drug concentration-time profile in
the target patient population, are known as 'population
PK studies'. The importance of population PK studies in
drug development and evaluation has been recognized by
the US FDA[6].
Although there are now statistical methods to analyse
sparse data from population PK studies, the design of
these population PK studies is not straightforward. Many
questions arise about how best to conduct these studies
including: how many patients should be included in the
study, what sampling scheme should be used, how many
different sampling schemes are required, and how many
patients need to be allocated to each of these sampling
schemes. Answers to these questions require prior knowl-
edge of the PK profile of the drug, the statistical methods
used to analyse data from population PK studies, and also
the practical constraints of sampling the patient popula-
tion. Examples of such constraints include the timing of
clinic visit, the maximum number of blood samples per
patient that can be collected, logistical constraints of clinic
workload, and whether a venous or capillary sample is
being collected. Currently population PK studies are
designed based on logistical, financial and ethical con-
straints, and the investigator's knowledge of the drug con-
centration-time profile. Although these factors are
important, they may result in a study of 'insufficient
design', which is unable to determine the desired PK
parameters and, therefore, unable to answer the funda-
mental questions that the population PK model was
intended to answer. In such a case the study is wasted.
Thus, there is both a scientific and an ethical imperative to
ensure PK studies are designed in such a way that they are
most likely to provide useable results.
A prime example of the applicability, but also the diffi-
culty of a population approach is seen with PK studies of
the artemisinin derivatives. These compounds are rapidly
absorbed and have very short elimination half-lives, typi-
cally less than one-hour [7], thus limiting options for
sampling schedules. Additionally, there is large inter-
patient and residual variability [8-13], reflecting in part
issues with the previous drug assay methodologies [14].
Another complication is that these drugs decompose in
the presence of iron(II) and, therefore, have to be ana-
lysed in plasma, and not in samples collected using the
dried blood spot technique. This is because during the
sample collection of dried blood spots, the blood cells
rupture and the protein configuration is changed during
the drying process. All of these factors may contribute to
an 'insufficient design' for population PK studies of these
drugs. Consequently, many of the PK analyses of the
artemisinin derivatives have either been unable to fit sat-
isfactory structural PK models to the data [9-11,13], fitMalaria Journal 2009, 8:189 http://www.malariajournal.com/content/8/1/189
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only a one-compartment structural PK model [9,13], or
required some of the PK parameters to be fixed [8,9,13].
In the study by Mithwani et al [9], the authors state that a
number of assumptions were required to obtain a satisfac-
tory fit of the model to the PK data due to the sparseness
of the data. Considering that the key PK information
required for the artemisinins is the maximum concentra-
tion, the area under the concentration-time profile, and
the time above a certain concentration, then, it is unethi-
cal to continue conducting these PK studies when the
sampling schedule will be insufficient to obtain accurately
this information.
These various problems could be overcome by designing
population PK studies using both information regarding
the practical constraints of sampling and optimal design
methods[15]. Optimal design methods provide designs
for population PK studies that are robust and efficient by
taking into account the concentration-time profile of the
drug, the statistical methods required to analyse popula-
tion PK data, practical constraints of sampling, and uncer-
tainty in the PK parameter values and structural PK
models. They can also help the researcher understand the
benefits and limitations of particular sampling schedules.
This paper will provide an introduction to optimal design
methods, including the prior information required for
optimal design methods, followed by a theoretical appli-
cation of the method for designing a population PK study
of intravenous artesunate.
Optimal design methods
Optimal design methods (also known as data-independ-
ent methods) for designing population PK studies have
only been available in the last decade [15-17]. The meth-
ods have been used for designing studies of the popula-
tion PK studies of itraconazole and ibuprofen in cystic
fibrosis patients [18,19], enoxaparin in patients with
acute coronary syndrome and deep vein thrombosis [20],
mizolastine in children with allergies [21], and flucona-
zole in people with HIV infection[22].
The methods require prior specification of:
￿ structural PK model (e.g. one-compartment PK
model with first-order absorption and elimination),
￿ PK parameter values (e.g. the values of the absorp-
tion rate constant (ka), clearance (CL), apparent vol-
ume of distribution (Vd)),
￿ the distribution of inter-individual variability for
each of the PK parameters and the values of the vari-
ance of each of these distributions,
￿ the residual variability model and the values of the
variance(s),
￿ study design space determined from sampling con-
straints (examples of sampling constraints: maximum
number of patients that can be recruited in the study;
maximum number of samples allowed per patient;
minimum time allowed between consecutive samples
for an individual; constrained times for the collection
of the blood samples, say 9 am to 5 pm; cost limita-
tions).
Figure 1 provides a flow-chart showing the components
involved in designing a population PK study using opti-
mal design methods. The study design team should have
clinical, pharmacological and statistical expertise.
It is important to note that optimal design methods, when
applied to PK studies, are dependent on the prior choice
of a particular set of parameters and model. The influence
of this dependence can be diluted by considering and
accounting for uncertainty in both the parameter values as
well as the plausible models. For example, Roos et al [22]
used optimal design methods to determine a PK design
for fluconazole in patients with HIV infection, using prior
information from a phase I study of healthy volunteers.
Since the prior information was from healthy volunteers
who may differ in their PK of fluconazole, five different
competing structural PK models were considered when
designing the study for the patients with HIV infection.
This ensured that the design proposed for HIV patients
was robust to uncertainty in the structural PK model.
In addition to consideration of uncertainty in the prior
information on the models, it is also important to con-
sider that the optimum design may not necessarily be
achievable in the clinic. Hence, it is important to consider
Flowchart for designing population pharmacokinetic studies  using optimal design methods Figure 1
Flowchart for designing population pharmacokinetic 
studies using optimal design methods.
Study design team
Identify study design constraints
Specify a set of plausible 
PK models and parameters
Derive optimal population PK study
Evaluate proposed 
population PK designMalaria Journal 2009, 8:189 http://www.malariajournal.com/content/8/1/189
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practical constraints such that an optimum design is
achieved conditioned on logistical components. An exam-
ple using constraints on optimal design methods is given
in [21]. In this work, a restrictive sampling schedule was
developed for a population PK study of mizolastine in
children. The study design constraints specified were a
maximum of four and six blood samples drawn from a
catheter in children aged 2 to 6 years and 6 to 12 years
respectively, and only one sample from children aged 6 to
12 years without a catheter. For children with a catheter,
blood sampling was restricted to the first six hours so they
would not have to remain for a long time in the hospital.
A population PK study, based on the derived optimal
design, was then conducted in children and the corre-
sponding data were successfully analysed using nonlinear
mixed effects modelling.
Optimal design methods have not been used for design-
ing population PK studies of anti-malarial treatments.
Derivation of optimal design
To derive the optimum design, several candidate designs
within the study constraints are considered, where the
amount of "information" (i.e. the precision of the param-
eters to be estimated) in each design is estimated. Thus the
design that contains the most "information" (i.e. the
design with the most precision) is considered optimal.
This is done mathematically by computing the Fisher
information matrix based on parameters of the structural
PK model, the inter-patient variability, and the residual
variability. A brief explanation of the Fisher information
matrix is given in Additional file 1. The design that maxi-
mizes the determinant of the Fisher information matrix
(the determinant can be thought of as a measure of the
volume of a matrix) also minimizes the determinant of
the estimation variance-covariance matrix. In other
words, optimizing a design based on the determinant of
the Fisher information matrix will provide a design that
has the highest precision (smallest standard errors) of the
parameters to be estimated. The optimum design is called
the D-optimal design. An optimization algorithm [23]
searches for the D-optimal design within the study design
constraints.
There are currently five open source software packages
that derive optimal designs for population PK studies
using the above D-optimal criteria, PFIM[24], Pop-
Des[25], PopED[26], and POPT and its complement Win-
POPT[27]. All of the packages evaluate sampling designs
using the same mathematical derivation of the Fisher
information matrix described above but vary in terms of
the extensibility of the package [28]. For this paper, fur-
ther discussion will be limited to the properties and fea-
tures of the software package POPT (WinPOPT is the
graphical user interface of POPT). POPT allows the user to
specify various study constraints (maximum number of
patients, maximum number of samples per patient, sam-
pling windows, minimum time between consecutive
blood samples). For prior specification of the structural
PK model, the user can select one of the available PK mod-
els or specify their own model using any parameteriza-
tion. Additionally, more than one structural PK model can
be selected (e.g. one- and two-compartment models). For
example, the structural PK model fitted to mefloquine
concentrations in population PK studies has been both
one-compartmental [29,30] and two-compartmental
[31]. Since it is not known which model may best describe
the data arising from the new study it is reasonable to con-
sider all previously published models as potential candi-
dates for the structural PK model. POPT then
automatically combines a measure of the "informative-
ness" of the design for each PK model into a single crite-
rion. This criterion can then be optimized using one of the
global search algorithms available within POPT to pro-
vide a design that is jointly optimal for estimation of
parameters from all candidate PK models.
Besides searching for the D-optimal design, POPT can
evaluate the performance of any particular design. This
informs researchers of the expected precision of the PK
parameters and any limitations of their proposed popula-
tion PK design.
Application of the optimal design method to 
design a population pharmacokinetic study of 
intravenous artesunate
The following hypothetical example is a population PK
study to determine the PK of dihydroartemisinin (the
principal biologically active metabolite) following a sin-
gle intravenous infusion (given as a rapid push) of 120 mg
of artesunate (circa 2.4 mg/kg). It is assumed that artesu-
nate is rapidly and completely converted to dihydroar-
temisinin. The study population are adults requiring
intravenous treatment for malaria.
Prior information regarding the structural PK model and
PK parameters is required. For this example a one-com-
partment model with first-order elimination was selected
to describe the PK profile of dihyroartemisinin:
The mean values chosen for Vd and CL were 38 L and 37
L.hr-1[32], and the PK profile simulated for these mean
values is presented in Figure 2. These values were selected
based on a preliminary review of literature. When design-
ing an actual population PK study, the parameter values
should be selected after an extensive literature review,
C
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which may provide a number of competing PK models
and parameter sets. This review needs to account for sam-
pling schemes and assay limitations, and adjust accord-
ingly, as many of the differences between PK studies of
anti-malarial drugs can be ascribed to differences in the
assays or sampling schedule. This ensures that the final
population PK design will have been optimized to pro-
vide good estimates of the parameters for all of the candi-
date PK models.
Inter-patient variability was assumed to be log-normally
distributed with the inter-patient standard deviation
equal to 0.5 for both Vd and CL, and covariance of Vd and
CL equal to zero. Residual variability was assumed to be
additive with a standard deviation of 200 ng.mL-1.
Sampling constraints were based on preliminary findings
of a survey of 16 experts, who currently conduct anti-
malarial PK studies in Asia and Africa. The constraints
identified for venous sampling of an adult were: mini-
mum time of 15 minutes between consecutive blood sam-
ples of a patient; and no more than 10 samples in the first
8 hours post drug administration.
The total number of patients to be recruited for our hypo-
thetical population PK study is constrained to be 50 and
the total number of blood samples that could be trans-
ported to a laboratory and assayed was fixed at 200.
Table 1 presents an evaluation of different sampling
designs for a total of 200 blood samples. The four elemen-
tary designs presented illustrate how alterations in the
number of patients and number of samples per patient
affect the precision of the parameter estimates and effi-
ciency of the design. All of the designs provide estimates
of the parameters within the expected precision limit
(expressed as 100 × standard error/estimate) of 15% for
the PK parameters, less than 40% for the inter-patient var-
iability, and less than 10% for the residual variability. The
designs with more patients and less samples per patient
improve the precision of the PK parameters and inter-
patient variability, and improve the overall efficiency by at
least 50%. The mixed design consisting of 10 patients
with 10 samples per patient and 25 patients with 4 sam-
ples per patient, had slightly less expected precision for
the PK parameters and inter-patient variability compared
with the sparse design (50 patients with 4 samples per
patient) but had marginally greater expected precision for
the residual variability.
These findings demonstrate the advantage of population
PK studies compared with traditional PK studies of a small
group of patients. The elementary designs presented have
fixed sampling times for each of the patients. For a study
in the field, which requires flexibility with blood sam-
pling (for logistic reasons), POPT can generate optimal
sampling windows around the fixed time points. Based on
the fixed sampling times of 0.25, 0.75, 2 and 4 hrs for 50
patients presented in Table 1, the four sampling windows
derived by POPT were 0.25–0.4, 0.6–1, 1.1–2.6, and 3–6
hrs. An evaluation of the sampling times at the bounda-
ries of the sampling windows, observed at least 95% sta-
tistically efficiency of the design with the fixed time
points.
The above elementary designs were evaluated and com-
pared based on the expected precision (calculated using
the Fisher information matrix) of the parameters, inter-
patient and residual variability. Once a final design has
been selected the design should also be evaluated by a
population PK analysis of simulated data[22]. At least 100
Pharmacokinetic profile of dihydroartemisinin following a sin- gle intravenous dose of 120 mg artesunate (Vd = 38 L, CL =  37 L.hr-1) Figure 2
Pharmacokinetic profile of dihydroartemisinin fol-
lowing a single intravenous dose of 120 mg artesu-
nate (Vd = 38 L, CL = 37 L.hr-1). Superimposed on the 
pharmacokinetic profile is the symbol "o" (Panel A) to repre-
sent the sampling times for the rich design in Table 1 (20 
patients, 10 samples per patient) and the symbol "O" (Panel 
B) to represent the sampling times for the sparse design in 
Table 1 (50 patients, 4 samples per patient).
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datasets of virtual patients should be simulated that
include uncertainty in the prior values of the PK parame-
ters and execution error in the conduct of the trial.
Conclusion
Population PK studies determine the drug concentration-
time profile in the target patient population and the
patient factors that cause changes in the drug concentra-
tion-time profile. These studies might be easier than tradi-
tional detailed PK studies to conduct, but they are
complex to design and analyse. The design of a popula-
tion PK study is very different to a sample size calculation
for the number of participants required for a randomized
controlled trial which can be performed using a hand cal-
culator. Optimal design is necessary to ensure we design
robust and efficient population PK studies that are able to
estimate precise PK parameters. This is the necessary pre-
requisite for optimizing dose regimens. It is especially
important for population PK studies of anti-malarials in
pregnant women and young children in whom blood
sampling cannot be extensive. Optimal design is a collab-
orative process involving clinicians, pharmacologists and
statisticians. This research team plans to provide optimal
designs for population PK studies of the artemisinin deriv-
atives and their partner drugs. Prior specification of the
structural PK model and parameters will be determined
from an extensive literature review. Study design con-
straints for all malaria patients will be identified from the
survey of clinicians and field workers actively involved in
anti-malarial pharmacokinetic studies.
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